Hans Wadenvik

4.9k total citations · 1 hit paper
124 papers, 3.3k citations indexed

About

Hans Wadenvik is a scholar working on Hematology, Genetics and Surgery. According to data from OpenAlex, Hans Wadenvik has authored 124 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Hematology, 39 papers in Genetics and 28 papers in Surgery. Recurrent topics in Hans Wadenvik's work include Platelet Disorders and Treatments (44 papers), Chronic Myeloid Leukemia Treatments (23 papers) and Blood groups and transfusion (20 papers). Hans Wadenvik is often cited by papers focused on Platelet Disorders and Treatments (44 papers), Chronic Myeloid Leukemia Treatments (23 papers) and Blood groups and transfusion (20 papers). Hans Wadenvik collaborates with scholars based in Sweden, Finland and China. Hans Wadenvik's co-authors include Jack Kutti, Bob Olsson, Per‐Ola Andersson, Stefan Jacobsson, Lena Carlsson, Margareta Jernås, Bo Risberg, Dick Stockelberg, Björn Carlsson and Lilian Tengborn and has published in prestigious journals such as Nature Medicine, Blood and Journal of Bone and Joint Surgery.

In The Last Decade

Hans Wadenvik

124 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura

2003 519 citations Bob Olsson, Per‐Ola Andersson et al. profile →

Peers

Countries citing papers authored by Hans Wadenvik

Since Specialization

Citations

This map shows the geographic impact of Hans Wadenvik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Wadenvik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Wadenvik more than expected).

Fields of papers citing papers by Hans Wadenvik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Wadenvik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Wadenvik. The network helps show where Hans Wadenvik may publish in the future.

Co-authorship network of co-authors of Hans Wadenvik

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Wadenvik. A scholar is included among the top collaborators of Hans Wadenvik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Wadenvik. Hans Wadenvik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study 2022 ·American Journal of Hematology ·Torsten Dahlén, Gustaf Edgren, Per Ljungman, (unknown), Johan Richter, Ulla Olsson‐Strömberg, Hans Wadenvik, Arta Dreimane, Kristina Myhr‐Eriksson, Jingcheng Zhao, Anders Själander, Martin Höglund, Leif Stenke	8
2	The impact of rituximab therapy in multiple sclerosis on cerebrospinal fluid cell gene expression 2013 ·Multiple Sclerosis Journal ·Margareta Jernås, Clas Malmeström, Intawat Nookaew, Hans Wadenvik, Jan Lycke, Bob Olsson	1
3	The autocrine motility factor receptor is overexpressed on the surface of B cells in Binet C chronic lymphocytic leukemia 2010 ·Medical Oncology ·(unknown), Bob Olsson, Margareta Jernås, Stefan Jacobsson, Birgitta Swolin, Ivan R. Nabi, Lena Carlsson, Hans Wadenvik	1
4	Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF 2008 ·Journal of Neuroimmunology ·Clas Malmeström, Jan Lycke, Sara Haghighi, O. Andersen, Lena Carlsson, Hans Wadenvik, Bob Olsson	59
5	Nabumetone 2004 ·Drugs ·Thomas Hedner, (unknown), (unknown), Hans Wadenvik, Kjell–Arne Ung, Anders Ekbom	71
6	Chronic idiopathic thrombocytopenic purpura (ITP): molecular mechanisms and implications for therapy 2004 ·Expert Reviews in Molecular Medicine ·Per‐Ola Andersson, Hans Wadenvik	23
7	Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura 2004 ·Thrombosis and Haemostasis ·Per‐Ola Andersson, Stefan Jacobsson, Lena Carlsson, Hans Wadenvik, Bob Olsson	57
8	Serum from patients with chronic idiopathic thrombocytopenic purpura frequently affect the platelet function 2002 ·Thrombosis Research ·Anna Olsson, Per‐Ola Andersson, Lilian Tengborn, Hans Wadenvik	20
9	Reduced transforming growth factor‐β1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura 2002 ·British Journal of Haematology ·Per‐Ola Andersson, Anna Olsson, Hans Wadenvik	54
10	The Relation Between Plasma Thrombopoietin and Erythropoietin Concentrations in Polycythaemia Vera and Essential Thrombocythaemia 2001 ·Leukemia & lymphoma ·Björn Andréasson, Göran Lindstedt, Dick Stockelberg, Hans Wadenvik, Jack Kutti	5
11	Incidence of chronic myeloproliferative disorders in the city of Göteborg, Sweden 1983–1992 2000 ·European Journal Of Haematology ·Börje Ridell, Jan Carneskog, Hans Wedel, Lars Vilén, Inge Høgh Dufva, Ulf‐Henrik Mellqvist, (unknown), Hans Wadenvik, Jack Kutti	20
12	Plasma Erythropoietin Concentrations in Polycythaemia Vera with Special Reference to Myelosuppressive Therapy 2000 ·Leukemia & lymphoma ·Björn Andréasson, Jan Carneskog, Göran Lindstedt, Per‐Arne Lundberg, Birgitta Swolin, Hans Wadenvik, Jack Kutti	14
13	The measurement of venous haematocrit in patients with polycythaemia vera 1999 ·Journal of Internal Medicine ·Björn Andréasson, Erik Wahlström, Staffan Jacobsson, Magnus Björkholm, Jan Samuelsson, Gunnar Birgegård, Hans Wadenvik, Jack Kutti	4
14	Impact of endogenous thrombopoietin levels on the differential diagnosis of essential thrombocythaemia and reactive thrombocytosis 1998 ·European Journal Of Haematology ·Ming Hou, Jan Carneskog, Ulf‐Henrik Mellqvist, Dick Stockelberg, Martin Hedberg, Hans Wadenvik, Jack Kutti	20
15	Immunoglobulins targeting both GPIIb/IIIa and GPIb/IX in chronic idiopathic thrombocytopenic purpura (ITP): evidence for at least two different IgG antibodies 1997 ·British Journal of Haematology ·Ming Hou, Dick Stockelberg, Jack Kutti, Hans Wadenvik	22
16	Assessment of spleen size using gamma camera scintigraphy in newly diagnosed patients with essential thrombocythaemia and polycythaemia vera 1996 ·European Journal Of Haematology ·Jan Carneskog, Hans Wadenvik, M Fjälling, Jack Kutti	15
17	Diagnostic and Differential Criteria of Essential Thrombocythemia and Reactive Thrombocytosis 1996 ·Leukemia & lymphoma ·Jack Kutti, Hans Wadenvik	60
18	Genotyping of the platelet‐specific alloantigen HPA‐5 (Br_a/Br_b) using polymerase chain reaction with sequence‐specific primers (PCR‐SSP) 1996 ·European Journal Of Haematology ·Ming Hou, (unknown), (unknown), Anders Elmgren, Lennart Rydberg, Jack Kutti, Hans Wadenvik	5
19	Leukocyte removal filtration of platelet concentrates. A study of platelet loss using ¹¹¹In‐labelled platelets and dynamic gamma camera scintigraphy 1991 ·European Journal Of Haematology ·Hans Wadenvik, Jack Kutti, Annika Lindholm	1
20	Splenic blood flow and intrasplenic platelet kinetics in relation to spleen volume 1987 ·British Journal of Haematology ·Hans Wadenvik, (unknown), Jack Kutti	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact